Pathologists Take Note: IBM’s Watson to Attack Cancer with Help of WellPoint and Cedars-Sinai

Goal of unique collaboration is to give physicians a more accurate way to diagnose and treat many types of cancer Two noteworthy healthcare organizations will collaborate with IBM (NYSE: IBM) to explore how IBM’s Watson can be used to help physicians deliver improved outcomes to patients. The collaboration involves one major health insurer and a prominent academic medical center in Los Angeles. WellPoint, Inc. (NYSE: WLP) will interact with oncology experts at the Cedars-Sinai Cancer Institute...

IBM Watson Picks Advisory Board—but No Pathologist

Clinical laboratory managers and pathologists have an opportunity to expand the presence of laboratory medicine IBM (NYSE: IBM) recently issued a press release announcing its new Watson Healthcare Advisory Board (WHAB). The board is comprised of healthcare leaders with a broad range of research, medical and business expertise. Unfortunately, that expertise does not include pathology or specialists in laboratory medicine. “Watson represents a technology breakthrough that can help...
;